A Study To Assess The Ability Of Tramadol, Naproxen And Oxycodone To Affect The Pain Thresholds Of Patients With Osteoarthritis Of The Thumb

Pfizer

Status and phase

Completed

Phase 1

Conditions

Osteoarthritis Thumbs

Treatments

Drug: Oxycodone

Drug: Tramadol

Drug: Naproxen

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00743587

A9001383

Details and patient eligibility

About

The purpose of this study is to determine if the measurement of pressure pain thresholds, in patients suffering osteoarthritis of the thumb, can be used to assess the activity of potential analgesic agents after a single dose. The study will use agents known to give pain relief in osteoarthritis as positive controls. These agents are: tramadol, naproxen and oxycodone.

Enrollment

36 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The clinical diagnosis of osteoarthritis of the hand, of at least 6 months duration.
Pain around one of the thumb joints due to osteoarthritis. The patient must report the average pain in this joint, in the week prior to screening, as at least 5 on an 11-point numerical pain rating scale at the time of screening.
The patient must demonstrate pressure pain at a thumb joint by reporting a pressure pain threshold lower than 300 kPa.

Exclusion criteria

Pregnant (as judged by a urine pregnancy test) or lactating female.
Other severe pain which may impair the assessment of the pain due to osteoarthritis.
Skin condition over the thumb joint, which will be used for pain threshold testing, that could interfere with the assessment of pain thresholds.
Known hypersensitivity to oxycodone, NSAIDS or tramadol.
Patients in whom NSAIDS, oxycodone or tramadol are contraindicated, or patients taking any concurrent medications which are contraindicated with any of the study medications .
An estimated renal clearance of less than 30 mL/min based on the Cockcroft Gault equation.
Use of prohibited medications as listed below, in the absence of appropriate washout periods:
Oral or intramuscular corticosteroids within 4 weeks prior to screening.
Monoamine oxidase inhibitors within 2 weeks of screening.
Analgesic agents, other than aspirin, or acetaminophen within 1 week prior to screening. (Aspirin use less than or equal to 325 mg per day for cardiovascular prophylaxis is permitted)
Acetaminophen up to 4 g/day may be used, provided it is not used in the 24 hours prior to any assessment of pain thresholds.
Intra-articular steroid injections into the study joint within 12 weeks, or to any other joint within 4 weeks, prior to screening.
History of chronic constipation, or of any condition which, in the opinion of the investigator, may put the patient at increased risk of respiratory depression.